Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of Advanced Maintenance Therapy in Elderly Ulcerative Colitis Patients in Long-Term Remission
jRCT1041250177Recruiting
- Sponsor
- Sugimoto Ken
- Start
- Jan 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in autoimmune colitis, sponsored by Sugimoto Ken. Primary endpoint: Clinical Remission Maintenance Rate at 48 Weeks After Discontinuation of Advanced Therapy. Started Jan 2026; status: recruiting.
02
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1041250177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041250177.